Breast cancer is the most common type of cancer in the UK, with around 55,000 new cases each year.
News
EMA licenses Mayzent for MS
Novartis also expects NICE and SMC decisions in the first half of 2020.
‘Weak antibiotic pipeline’ poses threat to AMR fight
Of the 60 products in development, very few seem to show benefit over existing treatments.
HIV transmissions fall by 71%
The UK is “well on its way towards our ambition of zero HIV transmissions by 2030.”
Heart failure market could surpass ‘$22bn by 2028’
Due to the aging global population, recent years have seen an increased prevalence of chronic HF.
INTCR 2020 closing for entry midnight on Thursday
The 2020 PharmaTimes International Clinical Researcher of the Year will be closing for entry at midnight this Thursday the 23rd of January.
Ibrance given NICE green light in breast cancer
The recommendation is based on data from the Phase III clinical trial, PALOMA-3, in which Ibrance delayed disease progression by 6.6 months.
Government health commitments just a ‘pipedream’
The plans were “ambitions”, and primary care is not being given the time, support and funding it needs.
Vitrakvi deemed ‘not cost-effective’ by NICE
The organisation, however, encourages further data collection on similar “game changing” histology independent cancer drugs.
Sepsis death rates ‘double’ previous figures
The new study included data from low- and middle-income countries, bringing the estimated total from 5.3 million deaths to 11 million.
Janssen submits Spravato expansion in EU
The J&J division seeks to expand the use to adults with major depressive disorder who have current suicidal ideation with intent.
A&E to scrap waiting targets?
The suggestion comes after December showed the “worst waiting times on record.”
NICE ‘OK’ for Lynparza
In a trial the drug stalled cancer growth for around 13.6 months compared to placebo.
Scientists discover ‘skin cancer suppressor’
Although it’s early stages, the research could eventually help develop new ways to combat melanoma.
UK cell and gene clinical trials up 45% from 2018
The industry currently supports over 3,000 jobs, with 1,700 roles in manufacturing and bioprocessing.
